Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer

Fig. 6

Screening of PI3K and mTOR inhibitors in organoids. A Dose–response curve showing the response of organoids to Alpelisib and Everolimus treatment. B Light microscopic photos showing Alpelisib and Everolimus treatment of CRC-1. Scale bar 200 μm. C Lollipop plot showing the top HALLMARK signaling pathways associated with Alpelisib treatment according to GSEA analysis. The horizontal coordinate is the Normalized Enrichment Score (NES) and the vertical axis shows the significant gene sets, with red dots for activation and blue for inhibition. FDR, false discovery rate. D Heatmap showing the effect of PI3K inhibitors on a panel of 6 lines organoids with wildtype PI3K. AUC, area under the curve of the dose–response curve

Back to article page